These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31437001)

  • 1. From Target to Drug: Generative Modeling for the Multimodal Structure-Based Ligand Design.
    Skalic M; Sabbadin D; Sattarov B; Sciabola S; De Fabritiis G
    Mol Pharm; 2019 Oct; 16(10):4282-4291. PubMed ID: 31437001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring conformational search protocols for ligand-based virtual screening and 3-D QSAR modeling.
    Cappel D; Dixon SL; Sherman W; Duan J
    J Comput Aided Mol Des; 2015 Feb; 29(2):165-82. PubMed ID: 25408244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The power of deep learning to ligand-based novel drug discovery.
    Baskin II
    Expert Opin Drug Discov; 2020 Jul; 15(7):755-764. PubMed ID: 32228116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep Convolutional Generative Adversarial Network (dcGAN) Models for Screening and Design of Small Molecules Targeting Cannabinoid Receptors.
    Bian Y; Wang J; Jun JJ; Xie XQ
    Mol Pharm; 2019 Nov; 16(11):4451-4460. PubMed ID: 31589460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNMG: Deep molecular generative model by fusion of 3D information for de novo drug design.
    Song T; Ren Y; Wang S; Han P; Wang L; Li X; Rodriguez-Patón A
    Methods; 2023 Mar; 211():10-22. PubMed ID: 36764588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging Crystal Engineering and Drug Discovery by Utilizing Intermolecular Interactions and Molecular Shapes in Crystals.
    Spackman PR; Yu LJ; Morton CJ; Parker MW; Bond CS; Spackman MA; Jayatilaka D; Thomas SP
    Angew Chem Int Ed Engl; 2019 Nov; 58(47):16780-16784. PubMed ID: 31385643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De Novo Molecular Design by Combining Deep Autoencoder Recurrent Neural Networks with Generative Topographic Mapping.
    Sattarov B; Baskin II; Horvath D; Marcou G; Bjerrum EJ; Varnek A
    J Chem Inf Model; 2019 Mar; 59(3):1182-1196. PubMed ID: 30785751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generative Recurrent Networks for De Novo Drug Design.
    Gupta A; Müller AT; Huisman BJH; Fuchs JA; Schneider P; Schneider G
    Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29095571
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Zhang J; Chen H
    J Chem Inf Model; 2022 Jul; 62(14):3291-3306. PubMed ID: 35793555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shape-Based Generative Modeling for de Novo Drug Design.
    Skalic M; Jiménez J; Sabbadin D; De Fabritiis G
    J Chem Inf Model; 2019 Mar; 59(3):1205-1214. PubMed ID: 30762364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep reinforcement learning for de novo drug design.
    Popova M; Isayev O; Tropsha A
    Sci Adv; 2018 Jul; 4(7):eaap7885. PubMed ID: 30050984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graph-based generative models for de Novo drug design.
    Xia X; Hu J; Wang Y; Zhang L; Liu Z
    Drug Discov Today Technol; 2019 Dec; 32-33():45-53. PubMed ID: 33386094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo molecular design with deep molecular generative models for PPI inhibitors.
    Wang J; Chu Y; Mao J; Jeon HN; Jin H; Zeb A; Jang Y; Cho KH; Song T; No KT
    Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35830870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function and structure-based screening of compounds, peptides and proteins to identify drug candidates.
    Malik V; Dhanjal JK; Kumari A; Radhakrishnan N; Singh K; Sundar D
    Methods; 2017 Dec; 131():10-21. PubMed ID: 28843611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process.
    Krishnan SR; Bung N; Srinivasan R; Roy A
    J Mol Graph Model; 2024 Jun; 129():108734. PubMed ID: 38442440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of structure- and ligand-based scoring functions for deep generative models: a GPCR case study.
    Thomas M; Smith RT; O'Boyle NM; de Graaf C; Bender A
    J Cheminform; 2021 May; 13(1):39. PubMed ID: 33985583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep Learning Applied to Ligand-Based De Novo Drug Design.
    Palazzesi F; Pozzan A
    Methods Mol Biol; 2022; 2390():273-299. PubMed ID: 34731474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical-Space-Based de Novo Design Method To Generate Drug-Like Molecules.
    Takeda S; Kaneko H; Funatsu K
    J Chem Inf Model; 2016 Oct; 56(10):1885-1893. PubMed ID: 27632418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.